Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview 8 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development 9 Products under Development by Stage of Development 9 Products under Development by Therapy Area 10 Products under Development by Indication 11 Products under Development by Companies 16 Products under Development by Universities/Institutes 23 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment 25 Assessment by Mechanism of Action 25 Assessment by Route of Administration 26 Assessment by Molecule Type 27 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development 29 Astellas Pharma Inc 29 BerGenBio ASA 29 Betta Pharmaceuticals Co Ltd 30 Celldex Therapeutics Inc 30 Daiichi Sankyo Co Ltd 31 Exelixis Inc 31 Ignyta Inc 33 Les Laboratoires Servier SAS 33 Mirati Therapeutics Inc 34 Ono Pharmaceutical Co Ltd 34 Oribase Pharma 35 Qurient Co Ltd 35 Rigel Pharmaceuticals Inc 36 SignalChem Lifesciences Corp 36 Takeda Pharmaceutical Co Ltd 36 Tolero Pharmaceuticals Inc 37 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles 38 Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 BGB-002 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 BGB-149 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 BGB-324 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 BGB-601 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 BPI-9016 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 cabozantinib s-malate - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 CT-053 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 CT-413 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 DS-1205 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Fusion Protein to Inhibit Axl Tyrosine kinase for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 gilteritinib fumarate - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 glesatinib - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 HOPE-777 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 ONO-7475 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Q-701 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 R-916562 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 RXDX-106 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 S-49076 - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 sitravatinib - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 SLC-0211 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Small Molecule to Inhibit AXL for Oncology - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 Small Molecules to Inhibit AXL, FLT3 and ARK5 for Solid Tumor and Hematological Tumor - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 TP-0903 - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products 103 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products 105 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones 106 Featured News & Press Releases 106 Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting 106 Nov 01, 2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting 106 Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer 107 Oct 16, 2017: Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma 107 Oct 16, 2017: Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma 108 Oct 16, 2017: Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma 109 Oct 12, 2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma 110 Oct 11, 2017: U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia 110 Oct 05, 2017: Tolero Pharma To Provide Update On TP-0903 At 9th International Conference On Leukemia And Hematologic Oncology 111 Oct 02, 2017: Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting 111 Sep 28, 2017: BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer 112 Sep 14, 2017: Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer 112 Sep 09, 2017: Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 114 Sep 08, 2017: Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults 115 Sep 06, 2017: Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress 116 Appendix 117 Methodology 117 Coverage 117 Secondary Research 117 Primary Research 117 Expert Panel Validation 117 Contact Us 117 Disclaimer 118

List of Tables Number of Products under Development by Stage of Development, H2 2017 9 Number of Products under Development by Therapy Areas, H2 2017 10 Number of Products under Development by Indications, H2 2017 11 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14 Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 15 Number of Products under Development by Companies, H2 2017 16 Products under Development by Companies, H2 2017 17 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 21 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 22 Number of Products under Investigation by Universities/Institutes, H2 2017 23 Products under Investigation by Universities/Institutes, H2 2017 24 Number of Products by Stage and Mechanism of Actions, H2 2017 25 Number of Products by Stage and Route of Administration, H2 2017 26 Number of Products by Stage and Molecule Type, H2 2017 28 Pipeline by Astellas Pharma Inc, H2 2017 29 Pipeline by BerGenBio ASA, H2 2017 30 Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017 30 Pipeline by Celldex Therapeutics Inc, H2 2017 31 Pipeline by Daiichi Sankyo Co Ltd, H2 2017 31 Pipeline by Exelixis Inc, H2 2017 32 Pipeline by Ignyta Inc, H2 2017 33 Pipeline by Les Laboratoires Servier SAS, H2 2017 33 Pipeline by Mirati Therapeutics Inc, H2 2017 34 Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 35 Pipeline by Oribase Pharma, H2 2017 35 Pipeline by Qurient Co Ltd, H2 2017 35 Pipeline by Rigel Pharmaceuticals Inc, H2 2017 36 Pipeline by SignalChem Lifesciences Corp, H2 2017 36 Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 37 Pipeline by Tolero Pharmaceuticals Inc, H2 2017 37 Dormant Products, H2 2017 103 Dormant Products, H2 2017 (Contd..1), H2 2017 104 Discontinued Products, H2 2017 105 List of Figures Number of Products under Development by Stage of Development, H2 2017 9 Number of Products under Development by Therapy Areas, H2 2017 10 Number of Products under Development by Top 10 Indications, H2 2017 11 Number of Products by Stage and Mechanism of Actions, H2 2017 25 Number of Products by Stage and Route of Administration, H2 2017 26 Number of Products by Molecule Types, H2 2017 27 Number of Products by Stage and Molecule Types, H2 2017 27

Astellas Pharma Inc BerGenBio ASA Betta Pharmaceuticals Co Ltd Celldex Therapeutics Inc Daiichi Sankyo Co Ltd Exelixis Inc Ignyta Inc Les Laboratoires Servier SAS Mirati Therapeutics Inc Ono Pharmaceutical Co Ltd Oribase Pharma Qurient Co Ltd Rigel Pharmaceuticals Inc SignalChem Lifesciences Corp Takeda Pharmaceutical Co Ltd Tolero Pharmaceuticals Inc